3.10Open3.10Pre Close0 Volume2 Open Interest370.00Strike Price0.00Turnover116.66%IV47.43%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry3.10Extrinsic Value100Contract SizeAmericanOptions Type0.1051Delta0.0026Gamma81.64Leverage Ratio-0.3147Theta0.0127Rho8.58Eff Leverage0.1073Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet